AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
May 3, 2024 7:06 AM EDT
UBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
May 3, 2024 6:35 AM EDT
RBC Capital analyst Gregory Renza lowered the price target on Amgen (NASDAQ: AMGN) to $328.00 (from $332.00) while maintaining a Outperform rating.
The analyst comments "GLP-1/GIPR, MariTides stated success on the ph.II interim data look internally takes the cake on the call,... More
May 3, 2024 5:53 AM EDT
Goldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $350.00 price target on Amgen (NASDAQ: AMGN)
The analyst comments "AMGN reported 1Q earnings (in-line top- and bottom-line; details within), with shares trading up significantly post-market (+15%; adding ~$20bn in market cap) as management provided a positive high-level interim update from the ongoing Ph2 study for MariTide in obesity, noting: (1) a differentiated profile vs. currently available therapies (e.g., LLYs Zepbound and NVOs Wegovy), as well as those in clinical development, (2) plans to rapidly advance a broad... More
